Search company, investor...

Changzhou Biowin Pharmaceutical

Founded Year



Corporate Majority | Acquired



About Changzhou Biowin Pharmaceutical

Changzhou Biowin Pharmaceutical engages in pharmaceutical research, development, production, process design, and technical consultation of synthetic pharmaceutical products. The company provides antibodies, antigens, and diagnostic test kits for heart disease, infectious disease, stroke, kidney function, diabetes, cancer, and bone metabolism disorder. It was founded in 2012 and is based in Changzhou, China. In October 2022, Shineco acquired a majority stake in Changzhou Biowin Pharmaceutical for $10M.

Headquarters Location

218 Fumin Road California Science and Technology Port

Changzhou, Jiangsu,


+86 519-88802789

Missing: Changzhou Biowin Pharmaceutical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Changzhou Biowin Pharmaceutical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Changzhou Biowin Pharmaceutical News

Shineco : Acquisition/Asset Disposal - Form 8-K

Jan 4, 2023

09:02a 01/04/2023 | 09:08am EST Message : SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): (December 31, 2022) SHINECO, INC. Delaware No. 20, Jinhe East Road,Chaoyang District Beijing, People's Republic of China 100020 (Zip Code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ ☐ ☐ ☐ Securities registered pursuant to Section 12(b) of the Act: Title of each class Common Stock, $0.001 par value SISI The NASDAQStock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.01 Completion of Acquisition or Disposition of Assets On December 30, 2022, Shineco Life Science Research Co., Ltd. ("Subsidiary"), a company established under the laws of China and indirect wholly owned subsidiary of Shineco, Inc. (the "Company") closed the acquisition of 51% of the issued equity interests of Changzhou Biowin Pharmaceutical Co., Ltd., a company established under the laws of China ("Biowin") pursuant to the previously announced stock purchase agreement, dated as of October 21, 2022, among Beijing Kanghuayuan Medicine Information Consulting Co., Ltd., a company established under the laws of China ("Seller") Biowin, the Company and Subsidiary (the "Agreement"). As the consideration for the acquisition, the Company paid to Seller US $9 million in cash and the Company issued 3,260,000 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock") to the equity holders of Biowen or any persons designated by Biowen. According to the Supplementary Agreement, dated as of December 30, 2022, by and among the Subsidiary, the Seller and Biowin, the Seller enjoys 51% of the issued equity interests of Biowin before January 1, 2023, and will transfer the 51% of the issued equity interests of Biowin together with its controlling rights of production and operation of Biowin to the Subsidiary from January 1, 2023. The foregoing summary of the Agreement is qualified in its entirety by reference to the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 3.02. Unregistered Sales of Equity Securities. The description of the Shares issued to the equity holders of Seller in Item 2.01 of this Report is incorporated by reference into this Item 3.02. The Company issued an aggregate of 3,260,000 Shares pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act, which exempts transactions by an issuer not involving any public offering pursuant to Regulation S under the Securities Act to non-United States residents who are not a "U.S. person" as defined in Rule 902(k) of Regulation S and are not acquiring the Shares for the account or benefit of any U.S. person. Item 9.01. Financial Statements and Exhibits. (a) Financial Statements of Businesses Acquired. The financial statements required by this item will be filed by amendment to this Current Report on Form 8-K within 71 calendar days after the date on which this Current Report is required to be filed. (b) Pro Forma Financial Information. The pro forma financial information required by this item will be filed by amendment to this Current Report on Form 8-K within 71 calendar days after the date on which this Current Report is required to be filed. (d) Exhibits:

Changzhou Biowin Pharmaceutical Frequently Asked Questions (FAQ)

  • When was Changzhou Biowin Pharmaceutical founded?

    Changzhou Biowin Pharmaceutical was founded in 1984.

  • Where is Changzhou Biowin Pharmaceutical's headquarters?

    Changzhou Biowin Pharmaceutical's headquarters is located at 218 Fumin Road, Changzhou.

  • What is Changzhou Biowin Pharmaceutical's latest funding round?

    Changzhou Biowin Pharmaceutical's latest funding round is Corporate Majority.

  • Who are the investors of Changzhou Biowin Pharmaceutical?

    Investors of Changzhou Biowin Pharmaceutical include Shineco.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.